Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29939188 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53ALDH1A1GAAMAPT | |
| SCHEMBL23726895 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53ALDH1A1GAAMAPT | |
| SCHEMBL26537652 | 0.80 | TP53 (0.41) | SMN1; SMN2TP53ALDH1A1GAAMAPT | |
| SCHEMBL21768206 | 0.78 | ALDH1A1 (0.37) | SMN1; SMN2TP53ALDH1A1GAAMAPT | |
| SCHEMBL21782043 | 0.78 | ALDH1A1 (0.37) | SMN1; SMN2TP53ALDH1A1GAAMAPT | |
| SCHEMBL21768249 | 0.78 | ALDH1A1 (0.37) | SMN1; SMN2TP53ALDH1A1GAAMAPT | |
| SCHEMBL17802980 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53ALDH1A1GAAMAPT | |
| SCHEMBL21781967 | 0.73 | ALDH1A1 (0.30) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL26544380 | 0.73 | GBA1 (0.31) | — | |
| SCHEMBL24250662 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| CN-116802182-A | Pyrazolopyridine derivatives and uses thereof | 诺华股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885TP53 1001/4885ALDH1A1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.